Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHO Solidarity Plus in hospitalized COVID-19 patients
IRCT20211221053470N1Phase 3Completed
- Sponsor
- World Health Organization
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of care + infliximab, Standard of care + imatinib and Standard of care (3 arms). Primary endpoints: In-hospital mortality from any cause, Initiation of ventilation and 1 more. Started Jan 2022; status: completed.
02
Drugs
infliximabimatinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20211221053470N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211221053470N1.